VENTAVIS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VENTAVIS (VENTAVIS).
Ventavis (iloprost) is a synthetic prostacyclin analog that causes vasodilation by increasing cyclic adenosine monophosphate (cAMP) levels in vascular smooth muscle cells, leading to relaxation and inhibition of platelet aggregation.
| Metabolism | Iloprost is metabolized primarily via beta-oxidation to inactive metabolites. Enzymes involved include acyl-CoA synthetases and other beta-oxidation enzymes. No significant CYP450 involvement. |
| Excretion | Renal: ~6% as unchanged drug; biliary/fecal: minimal; extensive hepatic metabolism with metabolites primarily excreted in urine (50-60% of total clearance). No significant renal or biliary excretion of parent drug. |
| Half-life | Terminal elimination half-life: 0.45–1.0 hour (intravenous). Short half-life necessitates continuous intravenous or frequent nebulized administration for sustained effect. |
| Protein binding | Approximately 60%; primarily to albumin (HSA). |
| Volume of Distribution | 0.36–0.48 L/kg (central volume); moderate distribution into tissues. |
| Bioavailability | Inhaled: ~30-40% (relative to intravenous); systemic absorption via lungs. |
| Onset of Action | Inhaled (via nebulizer): within 5 minutes; effect peaks at 15–30 minutes. Intravenous: rapid (seconds to minutes). |
| Duration of Action | Inhaled: 30–60 minutes (hemodynamic effects); requires dosing 6–9 times daily due to short duration. Intravenous: effect duration correlates with dosing interval; continuous infusion typically used. |
| Molecular Weight | 332.4 |
Inhaled: 2.5 mcg or 5 mcg via I-neb AAD system, 6 to 9 times daily (maximum 45 mcg/day). Titrate based on response and tolerability.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to limited data. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment; monitor for tolerability due to potential age-related comorbidities. |
| 1st trimester | Insufficient human data; based on animal studies, potential fetal risk cannot be ruled out. Use only if benefit outweighs risk. |
| 2nd trimester | Insufficient human data; based on animal studies, potential fetal risk cannot be ruled out. Use only if benefit outweighs risk. |
| 3rd trimester | May cause uterine relaxation and maternal hypotension; avoid use during labor. Fetal risk cannot be excluded. |
Clinical note
Comprehensive clinical and safety monograph for VENTAVIS (VENTAVIS).
| Placental transfer | Expected to cross placenta due to low molecular weight and lipid solubility; no human data available. |
| Breastfeeding | No human data available; drug likely excreted in milk due to low molecular weight. Use caution, consider infant risk. |
■ FDA Black Box Warning
Ventavis is intended for inhalation only via the I-neb AAD system or the Prodose AAD system; fatal events may occur if administered intravenously.
| Serious Effects |
Hypersensitivity to iloprost or any excipientPulmonary veno-occlusive diseaseSystemic systolic blood pressure <85 mmHgSevere left ventricular dysfunctionSignificant coronary artery disease or unstable anginaArrhythmias (ventricular tachycardia, atrial fibrillation with rapid ventricular rate)Cerebrovascular events within last 6 monthsBleeding disorders or active bleeding
| Precautions | Risk of syncope and hypotension; use caution in patients with systolic blood pressure <85 mmHg. Avoid abrupt discontinuation. Use with caution in patients with hepatic impairment (Child-Pugh class B or C) or renal impairment (creatinine clearance <30 mL/min). Not recommended for use in patients with pulmonary veno-occlusive disease. |
| Food/Dietary | No specific food interactions. Avoid alcohol and high-sodium foods if hypertensive; maintain a balanced diet as part of PAH management. |
Loading safety data…
| Lactation Rating |
| L5 (Contraindicated; no data or risk outweighs benefit) |
| Teratogenic Risk | FDA Pregnancy Category C. In animal studies, iloprost (the active ingredient) was teratogenic at doses higher than the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Potential fetal risks include skeletal abnormalities and increased post-implantation loss. Risk cannot be ruled out; use only if potential benefit justifies potential risk to the fetus. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of pulmonary hypertension exacerbation. Fetal monitoring includes ultrasound for fetal growth and amniotic fluid volume, and nonstress testing as clinically indicated. Assess for signs of preterm labor. Monitor for maternal bleeding risk due to antiplatelet effects. |
| Fertility Effects | No specific human studies on fertility. In animal studies, no adverse effects on fertility were observed at clinically relevant doses. Theoretical risk of impact on implantation due to vasodilatory effects; however, data are insufficient to draw conclusions. |
| Clinical Pearls | Ventavis (iloprost) is a synthetic prostacyclin analog used via inhalation for pulmonary arterial hypertension (PAH) to improve exercise capacity. Use a dedicated nebulizer; avoid contact with skin/eyes due to flushing and hypotension risk. Monitor blood pressure regularly. Do not mix with other medications in the nebulizer. Onset of action is rapid (5-10 min) but duration is short (30-60 min), requiring 6-9 inhalations daily. Syncope can occur; advise patients to sit during administration. |
| Patient Advice | Use Ventavis exactly as prescribed via the I-neb AAD system; do not change dose or frequency. · Inhale the medication while sitting upright; remain seated for a few minutes after use to prevent dizziness. · Report side effects like headache, flushing, jaw pain, or hypotension; syncope requires immediate medical attention. · Store vials in the refrigerator at 2-8°C (36-46°F); protect from light. Discard opened vials after 24 hours. · Do not use if the solution appears cloudy or contains particles. |